In recent studies, poly(lactide-co-glycolide) (PLGA) NPs modified with transferrin (Tf)loaded with a combination of TMZ and bortezomib, an O6-methylguanine-DNAmethyltransferase (MGMT) protein downregulating drug, presented astrategy to overcome drug resistance problems and improve TMZ efficacy.Tf conjugation improved targeting through BBB and increased the specificityof cargo delivery for GBM cells.48 Interestingly,TfR has been found to be overexpressed in GSCs, which suggests a potentialstrategy for treating GBM. The gene discussed is MGMT; the disease is glioblastoma.